Analyst Valuation RevisionAnalyst lowered the 12-month price target from $15 to $12, indicating reduced market expectations for near-term share performance.
Dilution RiskDilution from recent financing agreements increases share count, which can pressure earnings per share and per-share valuation.
Earnings Outlook UncertaintyLower analyst estimates highlight increased uncertainty around growth, creating risk of further downward revisions if commercialization and CDMO ramp fall short of expectations.